Search results
Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. ... Arun Kumar is the founder and chairman ...
Dec 11, 2014 · Arun Kumar, 53, Founder and Group CEO of drugmaker Strides Arcolab, made headlines in February last year when he sold Strides' injectibles business - called Agila Specialties - to US pharma giant ...
People also ask
What is the deal between Strides Arcolab & Ranbaxy Laboratories?
Why did Strides Arcolab change its name to strides Shasun Ltd?
Where does Strides Arcolab trade?
Will Arcolab & Shasun merge?
Boss Day Out: Strides Arcolab managing director Arun Kumar gets candid with NDTV as he takes us to the Bangalore-based pharmaceutical company's manufacturing...
- 7 min
- 18.8K
- NDTV
Jan 22, 2013 · Arun Kumar, the reclusive first-generation promoter of Bangalore-based pharma company Strides Arcolab Ltd, is understood to be actively involved in creating a family office type of fund to channel his personal wealth into fast-emerging companies. Kumar, who is believed to be finalising a $1-billion deal with global pharma majors to exit the specialties injectable business in Strides Arcolab ...
Sep 29, 2014 · PTI. NEW DELHI: In another instance of consolidation in Indian pharma sector, Strides Arcolab and Chennai-based Shasun Pharmaceuticals today announced their merger that will create an entity among the top 15 listed domestic drug makers with a turnover of over Rs 2,500 crore. "The Board of Directors of both the companies have approved a scheme ...
Jul 25, 2014 · NEW DELHI: Drug maker Strides Arcolab today reported over 12-fold jump in standalone net profit to Rs 26.79 crore for the quarter ended June 30 on improved margins across all segments. The company had reported a standalone net profit of Rs 2.15 crore in the corresponding period of last fiscal, Strides Arcolab said in a filing to the BSE.
Sep 11, 2015 · Arun Kumar: Now that the courts have approved the merger, we just have one last hurdle which is the FIPP clearances and then we are done. In terms of the true synergies in the pharmaceutical business, being in a regulated environment , the fully-integrated benefits in terms of us being able to use the Shasun capacities or APIs for a finished ...
